Fig. 3From: Evaluating the overall renal outcomes of sodium-glucose cotransporter-2 (SGLT2) inhibitors in patients with chronic kidney disease (CKD)Safety outcomes of AEs of SGLT2 inhibitors vs controlBack to article page
